[Mechanisms of the therapeutic action of vasodilator agents in cardiac insufficiency (review of the literature)].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy; D004285:Dogs; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D010208:Papaverine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D014665:Vasodilator Agents; C005317:drotaverin; D010208:Papaverine; D005996:Nitroglycerin; D010646:Phentolamine
Mekhanizmy lechebnogo deĭstviia vazodilatatorov pri serdechnoĭ nedostatochnosti (obzor literatury).